原发性胆汁性胆管炎是一种慢性自身免疫性胆汁淤积性疾病,主要发生在中老年女性,PBC的发病率和患病率在不同地区和时期差异性较大。原发性胆汁性胆管炎的发病机制尚不明确,现普遍认为PBC的发病涉及遗传因素、环境因素和免疫因素。目前,除了熊去氧胆酸(UDCA)、奥贝胆酸以及贝特类药物被批准用于PBC患者的治疗,更多的新型药物以及治疗方法正处于临床研发的不同阶段。Primary biliary cholangitis is a chronic autoimmune cholestasis disease, mainly occurring in middle-aged and elderly women. The incidence and prevalence of PBC vary greatly in different regions and periods. The pathogenesis of primary biliary cholangitis is still unclear, but it is generally believed that the pathogenesis of PBC involves genetic factors, environmental factors and immune factors. At present, in addition to Ursodeoxycholic Acid (UDCA), obecholic acid and bate drugs are approved for the treatment of PBC patients, more new drugs and treatments are in different stages of clinical research and development.
研究发现仍有一部分长期、规律接受一线核苷(酸)类似物治疗的慢性乙型肝炎患者存在低病毒血症,且低病毒血症与多种不良临床结局相关,因此低病毒血症已逐渐成为抗病毒治疗关注的难点。本文拟对一线核苷(酸)类似物经治慢性乙型肝炎患者低病毒血症的研究进展进行综述,以供临床参考。Researches have found that a portion of chronic hepatitis B patients receiving standard NAs antiviral therapy still develop Low-level viremia (LLV), which is associated with a variety of adverse clinical outcomes. Low-level viremia has gradually become a difficulty in antiviral treatment. This article aims to review the research progress of LLV in patients with chronic hepatitis B treated with first-line nucleoside (acid) analogues for clinical reference.
暂无评论